Clinical Trials Logo

Methamphetamine Use Disorder clinical trials

View clinical trials related to Methamphetamine Use Disorder.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04713124 Completed - Clinical trials for Methamphetamine Use Disorder

A Telephone-delievered Intervention to Reduce Methamphetamine Use

R2C-M
Start date: February 4, 2021
Phase: N/A
Study type: Interventional

Australia has one of the highest rates of methamphetamine use in the world; however, uptake of face-to-face psychological treatment remains extremely low due to numerous individual (e.g. stigma, shame) and structural (e.g. service availability, geography) barriers to accessing care. Addressing these barriers through the provision of alternative treatment delivery models is imperative, particularly as effective and earlier intervention is likely to reduce the need for more costly and intensive treatment resulting from escalating methamphetamine use. In this project, the investigators will conduct the first double-blind, parallel-group, randomised controlled trial (RCT) examining the effectiveness of the structured telephone-delivered intervention, Ready2Change (R2C), among participants with methamphetamine use problems (R2C-M). Cost effectiveness of R2C-M will also be investigated. Factors influencing program implementation will be evaluated to inform the scalability of this intervention for practice nationally, and for replication internationally.

NCT ID: NCT04178993 Completed - Clinical trials for Methamphetamine Use Disorder

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

Start date: September 1, 2019
Phase: Phase 1
Study type: Interventional

This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.

NCT ID: NCT03078075 Completed - Clinical trials for Methamphetamine Use Disorder

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

ADAPT-2
Start date: May 5, 2017
Phase: Phase 3
Study type: Interventional

This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.

NCT ID: NCT01982643 Completed - Clinical trials for Methamphetamine Use Disorder

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

ADAPT
Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a combination of extended-release depot naltrexone plus extended-release bupropion as a potential pharmacotherapy for methamphetamine (MA) use disorder.

NCT ID: NCT00572234 Completed - Clinical trials for Methamphetamine Use Disorder

Bupropion in the Treatment of Methamphetamine Dependence

Start date: August 31, 2007
Phase: N/A
Study type: Interventional

Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for methamphetamine have been identified. This study is a collaborative pre-clinical and clinical partnership examining bupropion in the treatment of methamphetamine dependence.